Lucid Diagnostics Inc. (LUCD) News
Follow Lucid Diagnostics Inc. (LUCD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ascendiant Capital raises Lucid Diagnostics target to $9.50
Ascendiant Capital raised its Lucid Diagnostics price target to $9.50 per share from $9.25.
EQUITY | Aug 27, 2026, 11:52 AM UTC
L
Lucid Diagnostics reports Q2 revenue of $1.5 million, adds coverage milestone
Lucid Diagnostics said second-quarter revenue rose about 17% from the prior quarter to $1.5 million as it performed 2,770 EsoGuard tests and secured its first laboratory benefit manager commercial coverage policy from Co
EARNINGS | Aug 13, 2026, 03:11 PM UTC